| Document |
Document Title |
|
WO/2011/014707A2 |
Compounds having activity for lowering parathyroid hormone levels are described. In one embodiment, the compounds are comprised of a contiguous sequence of subunits, X1 - X2 - X3 - X4 - X5 - X6 - X7, wherein the X1 subunit comprises a th...
|
|
WO/2011/013470A1 |
Disclosed is an autoantibody production inhibitor which can inhibit an autoantibody specifically and can prevent or treat autoantibody autoimmune diseases effectively. The autoantibody production inhibitor is characterized by comprising,...
|
|
WO/2011/013644A1 |
Disclosed is a substituted piperidine compound useful as a therapeutic agent for high blood pressure, etc. Disclosed is a compound, etc., having a general formula (I) [in the formula, R1 represents H, an optionally substituted alkyl, phe...
|
|
WO/2011/012707A1 |
The present invention relates to in vitro and in vivo methods for the generation of pancreatic β-cells, comprising the step of providing at least one pancreatic α-cell or at least one precursor cell with Pax-4 or a nucleic acid encodin...
|
|
WO/2011/011965A1 |
A decapeptide derivative of formula (I) possessing hydantoin structure, a preparation method thereof, a pharmaceutical composition containing said decapeptide derivative and applications thereof in preparing medications are provided. The...
|
|
WO/2011/012883A1 |
Compounds of formula (I): wherein: W is O, N-H, N-alky!, N-alkenyl, N-alkynyl, N-aryl, N-heteroaryl or S; each X is independently CH or N; R1 is formula (b) or R3 is H, alkyl, NH2, OH, =0 or halogen; each A and B are independently CH or ...
|
|
WO/2011/010080A1 |
The invention relates to Boswellia frereana and particularly an extract of same for treating a range of inflammatory disorder or conditions selected from the group comprising: articular cartilage degradation or arthritides, osteoarthriti...
|
|
WO/2011/011508A1 |
The present invention relates to certain 4,5-dihydro-3H-spiro[benzo[b]-[1,4]oxazepine compounds of the Formula (I) or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, m, n, o, and p are as herein described. In addi...
|
|
WO/2011/007865A1 |
Disclosed is an agent for inhibiting increase in postprandial blood insulin level, which contains a polyglutamic acid as an active ingredient.
|
|
WO/2011/007839A1 |
Novel 4-(3-butynyl)aminopyrimidine derivatives represented by general formula [I] are useful as pest control agents. In general formula [I], R1 is a mono- or bi-cyclic ring which may contains 0 to 3 heteroatoms, for example, phenyl or ox...
|
|
WO/2011/006497A1 |
The invention provides materials and methods for promoting weight loss or preventing weight gain, and in the treatment of diabetes and associated metabolic disorders. In particular, the invention provides novel acylated glucagon analogue...
|
|
WO/2011/005969A2 |
The invention is directed to compounds according to formula (I): where R1 is L1C(O)OT or L1C(O)OL2C(O)OT; R2 is a substituted or unsubstituted C1-C10 alkyl, C2-C10 alkenyl, or C2-C10 alkynyl, or R1; n is an integer from 0 to 5; each R3 i...
|
|
WO/2011/002332A1 |
The invention relates to peptides which manifest anti-stress activity and have the general formula (I) R1-Lys1-Arg2-Pro3-R2 of sequence 1 [SEQ ID NO:1] or R1-Lys1-Arg2-Arg3-Pro4-R2 of sequence 2 [SEQ ID NO: 2], wherein R1 = NH2 or CH3CO ...
|
|
WO/2011/000210A1 |
A permeation enhancer and its use in the transdermal drug delivery system. The permeation enhancer comprises ethers and alcohols which are not C6-C18 fatty alcohols. It may further contains C6-C18 fatty acids or C6-C18 fatty alcohols. Th...
|
|
WO/2011/002001A1 |
Disclosed is a novel medicinal agent useful for the treatment of hyperglycemia-related diseases or the like. Specifically disclosed is a medicinal agent useful for the treatment of hyperglycemia-related diseases or the like, which compri...
|
|
WO/2010/149273A1 |
The invention relates to pharmaceutical compositions for emergency contraception, to the use of levonorgestrel in combination with cox inhibitors for the production of pharmaceutical compositions for the afore-mentioned purpose, and to a...
|
|
WO/2010/151281A1 |
Methods to treat and provide pain relief for damaged and degenerated tissues of a musculoskeletal joint are disclosed. These methods include introducing into, around and/or on the musculoskeletal joint an effective amount of a pharmaceut...
|
|
WO/2010/150837A1 |
A therapeutic agent for hyperparathyroidism, secondary hyperparathyroidism, primary hyperparathyroidism, renal osteodystrophy, hypercalcemia or the like, which has a calcium sensing receptor activation activity and comprises a compound r...
|
|
WO/2010/145125A1 |
Provided is a type of highly purified human menopausal gonadotropin, the HPLC purity of which is not less than 95%, and the impurity HPLC content of which is not more than 5%. Also provided are the preparing method and uses of the said h...
|
|
WO/2010/147234A1 |
To provide a melanin concentrating hormone receptor antagonist useful as medicines for central system disorders, cardiovascular disorders and metabolic disorders. Provided is a compound of a formula (I): wherein R1a and R1b each are a hy...
|
|
WO/2010/146299A1 |
The invention relates to the compounds of formula (I), where: R is a (C1-C6)alkyl or halo(C1-C6)alkyl group; A is a carbon atom optionally substituted by one or more hydrogen atoms or (C1-C6)alkyl groups; R5 is one or two carbon atoms su...
|
|
WO/2010/145903A1 |
The present invention thus concerns a method for treating and/or preventing rickets, osteoporosis, osteomalacia, psoriasis, autoimmune diseases such as multiple sclerosis or type I diabetes, hyperparathyroidism, benign prostate hyperplas...
|
|
WO/2010/142060A1 |
The present invention provides decapeptide derivatives with LHRH receptor antagonizing activity, pituitary gonadotrophin secretion inhibiting effect, and sex gland steroid hormone secretion inhibiting effect, the preparation process ther...
|
|
WO/2010/143803A2 |
Provided are novel nicotinamide derivatives and pharmaceutically acceptable salts thereof with anti-androgen effects, preparing processes of the same and antiandrogens containing the same as active ingredients. More particularly, the sai...
|
|
WO/2010/142705A1 |
The present invention relates to substituted steroid compounds having the formula (I) Wherein R1 is H or halogen; R2 is H, (1C-4C)alkyl, (1C-4C)acyl, glucuronyl or sulfamoyl; R3 is H or halogen; R4 is H, (1C-4C)alkyl, (2C-4C)alkenyl or (...
|
|
WO/2010/140401A1 |
For producing a microneedle array comprising a water-soluble stringy polymeric material as a base and a polymeric drug, e.g., a vaccinal antigen or insulin, contained in the tips, there is a desire for a substrate with which it is possib...
|
|
WO/2010/136940A1 |
This invention relates to novel glucocorticoid receptor agonists of formula (I) and to processes and intermediates for their preparation. The present invention also relates to pharmaceutical compositions containing these compounds, to th...
|
|
WO/2010/131191A1 |
The present invention relates to thiazolidin-4-one and [1,3]-thiazinan-4-one compounds of formula (I) wherein X, Y, R3 and R4 are as described in the description, or pharmaceutically acceptable salts thereof, for the prevention or treatm...
|
|
WO/2010/132743A1 |
New chemical entities which comprise corticosteroids and phosphorylated β-agonists for use in therapy and compositions comprising and processes for preparing the same are provided.
|
|
WO/2010/128141A1 |
The invention relates to stable pharmaceutical compositions comprising a therapeutic peptide derivatized with a property-modifying group, wherein the property-modifying group is conjugated to the peptide by use of a linker comprising an ...
|
|
WO/2009/135581A9 |
The present invention relates to NIP thiazole derivatives of formula (I) as selective inhibitors of the enzyme 11-beta-hydroxysteroid dehydrogenase type 1 (11-β-HSD-1) and the use of such compounds for the treatment and prevention of me...
|
|
WO/2010/124322A1 |
The invention relates to a method of prevention or treatment of a condition such as magnesium deficiency or deficit or abnormality, creatine or creatine phosphate (phosphocreatine) deficiency or abnormality, parathyroid hormone (PTH) exc...
|
|
WO/2010/126164A1 |
To provide an indole compound having a human QRFP receptor antagonistic activity and useful as a preventive or a remedy for various disorders. A compound of a formula (I) or a pharmaceutically-acceptable salt thereof is provided: [wherei...
|
|
WO/2010/126030A1 |
Disclosed is a compound represented by formula (1) or a pharmacologically acceptable salt thereof. (In the formula, W, X, Y, R1, R2, R33, R34, m and n are as defined in the claims.)
|
|
WO/2010/126163A1 |
The present invention relates to a compound represented by a formula (I): wherein X is a group represented by or the like; Y is a group represented by or the like; and Ar1 is a group represented by or a pharmaceutically acceptable salt t...
|
|
WO/2010/126167A1 |
Disclosed are: a compound represented by formula (I), or a salt, solvate or physiologically functional derivative thereof; and a pharmaceutical composition comprising the compound or the salt, solvate or physiologically functional deriva...
|
|
WO/2010/125891A1 |
For the purpose of treating/preventing disorders or diseases associated with estrogen deficiency, an extract from a hypha of Agaricus blazei Murrill and a brefeldin A component are utilized.
|
|
WO/2010/126953A1 |
New chemical entities which comprise corticosteroids and phosphorylated β- agonists for use in therapy and compositions comprising and processes for preparing the same are provided.
|
|
WO/2010/125799A1 |
Disclosed is a compound represented by formula (I), which inhibits the action of PI3K, controls a number of biological processes, such as the growth, differentiation, survival, proliferation, migration and metabolism of cells, and, there...
|
|
WO/2010/122980A1 |
Disclosed is a heterocyclic derivative which has a thyroid hormone β receptor agonistic activity and is therefore effective for the prevention or treatment of diseases associated with the activity. Specifically disclosed are: a compound...
|
|
WO/2010/122385A1 |
The invention relates to a complex of insulin and a polysaccharide comprising carboxylic functional groups, said polysaccharide being selected from among the polysaccharides functionalized by at least one phenylalanine derivative, in par...
|
|
WO/2010/097576A9 |
The present invention provides compounds of formula (1) compositions comprising such compounds; the use of such compounds in therapy (such as in the treatment of dysmenorrhoea); and methods of treating patients with such compounds; where...
|
|
WO/2010/120889A1 |
The present application relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein the variables are'as defined in the claims. The present application also relates to the treatment of metabolic syndrome o...
|
|
WO/2010/119990A1 |
A pharmaceutical composition comprising a combination of (A) a 1-thio-D-glucitol compound represented by the general formula (I) and (B) at least one member of the group consisting of biguanides, insulin secretagogues, insulin sensitizer...
|
|
WO/2010/118025A1 |
Described herein are compounds which exhibit progesterone antagonistic effects and methods of treating cancer using such compounds.
|
|
WO/2010/115615A1 |
The present invention relates to improved glucocorticoid therapy and to treatment or prevention of a number of disorders that are due to a diminished or disrupted endogenous glucocorticoid secretory pattern. The invention is based on the...
|
|
WO/2010/115556A1 |
The invention relates to a compound having the formula of structure (I): or a pharmaceutically acceptable salt thereof, for use in treating a LH receptor-related condition.
|
|
WO/2010/113860A1 |
Disclosed is a novel compound that has an antagonist action on a calcium receptor. Specifically disclosed is a compound represented by general formula (I) or a pharmacologically acceptable salt thereof. (In the formula, the substituents ...
|
|
WO/2010/113834A1 |
Disclosed is a novel and excellent method for preventing and/or treating cannabinoid-2 receptor-related diseases, which is based on an agonist action on cannabinoid-2 receptors. Specifically disclosed is a heterocyclic derivative mainly ...
|
|
WO/2010/111845A1 |
Provided are a high specific activity human menopausal gonadotropin, as well as preparation method and use thereof. The specific activity of said high specific activity menopausal gonadotropin is no less than 5000 FSH UI/mg protein. Also...
|
